Moreover, oral administration of ABC294640 supressed HT-29 xenografts growth in nude mice, which puts forward that targeting sphingosine kinase 2 by ABC294640 could provide a novel therapeutic opportunity for BRAF mutant colon cancer. Here, BRAF is linked to malignant colon neoplasm.